Pegylated interferon-α2b plus ribavirin therapy in patients with hepatitis C and psychiatric disorders: results of a cohort study

2010 ◽  
Vol 15 (4) ◽  
pp. 599-606 ◽  
Author(s):  
Jean-Philippe Lang ◽  
◽  
Pascal Melin ◽  
Denis Ouzan ◽  
Michel Rotily ◽  
...  
Keyword(s):  
Cohort Study ◽  
Hepatitis C ◽  
Psychiatric Disorders ◽  
Pegylated Interferon ◽  
Interferon Α2b

scholarly journals Efficacy and Safety of Pegylated Interferon-α2b Plus Ribavirin for the Treatment of Chronic Hepatitis C in HIV-Infected Patients

2006 ◽  
Vol 22 (4) ◽  
pp. 315-320 ◽  
Author(s):  
Miguel Santin ◽  
Evelyn Shaw ◽  
M. Jose Garcia ◽  
Antonio Delejido ◽  
Eduardo Rodriguez De Castro ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Pegylated Interferon ◽  
Efficacy And Safety ◽  
Interferon Α2b

scholarly journals Pegylated interferon-α2b and ribavirin combination therapy for pediatric patients with chronic hepatitis C

Kanzo ◽  
2008 ◽  
Vol 49 (8) ◽  
pp. 386-388 ◽  
Author(s):  
Ayano Inui ◽  
Haruki Komatsu ◽  
Tsuyoshi Sogo ◽  
Takuji Hashimoto ◽  
Tomoo Fujisawa
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Combination Therapy ◽  
Chronic Hepatitis C ◽  
Pediatric Patients ◽  
Pegylated Interferon ◽  
Interferon Α2b

A case of deep venous thrombosis associated with pegylated interferon α2b plus ribavirin treatment of chronic hepatitis C

2007 ◽  
Vol 41 (12) ◽  
pp. 1231-1236 ◽  
Author(s):  
Chiaki Okuse ◽  
Kayo Adachi ◽  
Yoshiki Katakura ◽  
Kotaro Matsunaga ◽  
Toshiya Ishii ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Venous Thrombosis ◽  
Deep Venous Thrombosis ◽  
Chronic Hepatitis C ◽  
Pegylated Interferon ◽  
Interferon Α2b

Differential Antiviral Effects of Pegylated Interferon-α2a and Pegylated Interferon-α2b in Chronic Hepatitis C

2014 ◽  
Vol 34 (12) ◽  
pp. 871-878
Author(s):  
Emanuele Durante-Mangoni ◽  
Antonio Parrella ◽  
Domenico Iossa ◽  
Roberto Andini ◽  
Rosa Molaro ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Pegylated Interferon ◽  
Antiviral Effects ◽  
Interferon Α2a ◽  
Interferon Α2b

scholarly journals Long-term surveillance of liver histological changes in chronic hepatitis C patients completing pegylated interferon-α plus ribavirin therapy: an observational cohort study

2022 ◽  
Vol 13 ◽  
pp. 204062232110676
Author(s):  
Ming-Han Hsieh ◽  
Tzu-Yu Kao ◽  
Ting-Hui Hsieh ◽  
Chun-Chi Kao ◽  
Cheng-Yuan Peng ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Cohort Study ◽  
Hepatitis C ◽  
Pegylated Interferon ◽  
Observational Cohort Study ◽  
Histological Changes ◽  
Entire Cohort ◽  
Fibrosis Progression ◽  
Observational Cohort

Background: For chronic hepatitis C (CHC) patients completing pegylated interferon (PegIFN)-α/ribavirin therapy, long-term liver histological changes remain largely unexplored. Methods: This observational cohort study included 85 CHC patients completing PegIFN-α/ribavirin therapy with liver biopsies performed at baseline and the end of surveillance (EOS). Median years between paired biopsies were 6.75 (interquartile range: 5.63–7.54). Results: In patients with baseline METAVIR fibrosis stages (F) <4 (able to undergo fibrosis progression; n = 77), cases achieving sustained virological response (SVR) ( n = 52) had a significantly lower rate of fibrosis progression than non-SVR cases ( n = 25) (3.8% versus 24.0%, p = 0.012). Among the entire cohort ( n = 85), the rate of activity response [METAVIR activity grades (A) decreasing or maintaining at A0] in SVR cases ( n = 59) was significantly higher than that in non-SVR cases ( n = 26) (94.9% versus 65.4%, p = 0.001). For SVR cases among the entire cohort, independent predictors of fibrosis clearance included baseline F <2 [odds ratio (OR) = 7.877, p = 0.042] and aspartate transaminase (AST) levels declining by >70% at EOS compared with baseline (OR = 9.013, p = 0.038). For non-SVR cases among the entire cohort, baseline AST levels >80 U/l and glucose levels ⩽ 105 mg/dl independently predicted significant fibrosis (F2/F3/F4) at EOS (OR = 12.558, p = 0.049) and activity response (OR = 17.741, p = 0.047), respectively. Conclusions: Among CHC patients completing PegIFN-α/ribavirin therapy, SVR lowers the risk of liver histological progression but does not guarantee fibrosis clearance. For SVR cases, those with baseline F ⩾ 2 or without significantly declined follow-up AST levels should be specifically monitored. As for non-SVR cases, those with a higher baseline AST or glucose level should preferentially receive retreatment.

Sign in / Sign up

Export Citation Format

Share Document